Breaking News

Oxford Biomedical Awarded NIH Grant

To develop proteomic toxicity screening panel

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oxford Biomedical Research, Inc. has been awarded a Phase II Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences. The grant, valued at $1.2 million, is for the development of a panel of tests designed to use GST proteins as more sensitive and specific biomarkers to detect toxicity and differentiate potential toxic effects to multiple organs.   GST proteins, found in many tissues and organs, play an important role in the elimination of drugs and env...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters